Don’t miss the latest developments in business and finance.

Dr Reddy's reports Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore

DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.

Dr Reddy's
The US business grew by 9 per cent YoY to Rs 1,739 crore
Sohini Das
1 min read Last Updated : Jan 30 2021 | 12:49 AM IST
DRL on Friday reported a consolidated net profit of Rs 20 crore in the third quarter against a loss of Rs 569.7 crore in the year-before period.

DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment. 

The firm posted a 12 per cent year-on-year growth in revenues to Rs 4,930 crore and a 10 per cent YoY growth in Ebitda to Rs 1,185 crore while the Ebitda margin stood at 24 per cent.

The US business grew by 9 per cent YoY to Rs 1,739 crore while India posted an increase by 26 per cent YoY to Rs 959 crore.

Topics :Dr Reddy's LaboratoriesQ3 results